Abstract 426P
Background
In SELECT, PFS was significantly longer with LEN 24 mg/d (median: 18.3 mos) vs placebo (median: 3.6 mos; HR 0.21, 99% CI: 0.14–0.31) in pts with RR-DTC; however, the dose-reduction rate due to TEAEs was 68%. This study was designed to evaluate if a starting dose of LEN 18 mg/d could maintain efficacy and reduce toxicity in pts with RR-DTC.
Methods
In this double-blind study, pts ≥18 years (N=152) were randomized 1:1 to receive daily oral LEN at a starting dose of 24 mg (n=75) or 18 mg (n=77): ‘LEN24’ and ‘LEN18’ arms, respectively. The primary efficacy endpoint was ORR as of week 24 (ORRwk24). ORRwk24 analysis was based on a noninferiority test on the odds ratio (OR; noninferiority margin of 0.4 on OR scale). Tumors were assessed by investigators per RECIST v1.1. The primary safety endpoint was the rate of TEAEs grade ≥3 as of wk 24.
Results
The ORRwk24 was 57.3% (95% CI: 46.1–68.5) in LEN24 and 40.3% (95% CI: 29.3–51.2) in LEN18. OR (18/24 mg) 0.50 (95% CI: 0.26–0.96) did not meet criteria for noninferiority. Overall ORR was 64.0% (95% CI: 53.1–74.9) in LEN24 and 46.8% (95% CI: 35.6–57.9) in LEN18 (OR [18/24 mg] 0.50, 95% CI: 0.26–0.95). Median PFS was not reached (NR) in LEN24 (95% CI: 22.1–NR) vs 24.4 mos in LEN18 (95% CI: 14.7–NR) (HR: 1.44, 95% CI: 0.76–2.74). As of wk 24, there was a nonclinically relevant difference in the rate of TEAEs grade ≥3 of 4.2% (95% CI: −19.8–11.4 [LEN24, 61.3% of pts; LEN18, 57.1% of pts]). The most common TEAE grade ≥3 (24/18 mg) as of wk 24 was hypertension (25.3%/19.5%). Overall, TEAEs resulted in dose reduction in 69.3% of pts in LEN24 and 59.7% of pts in LEN18; 14.7% of pts in LEN24 and 16.9% of pts in LEN18 had a TEAE that led to discontinuation.
Conclusions
This study did not show noninferiority of LEN 18 mg vs LEN 24 mg based on the ORRwk24 analysis. ORRwk24 for LEN24 (57%) was consistent with that seen by investigator assessment in SELECT (59%). Incidences of grade ≥3 TEAEs through wk 24 were similar between treatment arms, and no new or unexpected safety signals were observed. These data support selection of LEN 24 mg/d as an appropriate starting dose for pts with RR-DTC.
Clinical trial identification
NCT02702388.
Editorial acknowledgement
Medical writing support was provided by Heather A. Mitchell, PhD, of Oxford PharmaGenesis, Newtown, PA and was funded by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
M.S. Brose: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bayer; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Eisai; Advisory/Consultancy, Research grant/Funding (self): Blueprint Medicines; Advisory/Consultancy, Research grant/Funding (self): Loxo; Advisory/Consultancy, Research grant/Funding (self): Novartis; Advisory/Consultancy: Genzyme; Advisory/Consultancy: Bristol-Myers Squibb; Research grant/Funding (self): Roche/Genentech; Research grant/Funding (self): Exelixis. B. Konda: Research grant/Funding (institution): Advanced Accelerator Applications; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Xencor; Research grant/Funding (institution): Bristol-Myers Squibb. C. de la Fouchardiere: Honoraria (self): Eisai; Honoraria (self), Non-remunerated activity/ies: Roche; Honoraria (self), Non-remunerated activity/ies: Servier; Honoraria (self), Non-remunerated activity/ies: Amgen; Honoraria (self), Non-remunerated activity/ies: Pierre Fabre Oncologie; Honoraria (self), Non-remunerated activity/ies: Bayer; Honoraria (self), Non-remunerated activity/ies: Bristol-Myers Squibb. B.G.M. Hughes: Advisory/Consultancy: Roche; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Merck Sharp and Dohme; Advisory/Consultancy: Eisai; Advisory/Consultancy: Takeda; Research grant/Funding (self): Amgen. A.G. Gianoukakis: Advisory/Consultancy: Eisai; Advisory/Consultancy: Bayer; Advisory/Consultancy: Loxo-Lilly. I. Romanov: Honoraria (self): Eisai; Honoraria (self): Merck Serono; Honoraria (self): Bristol-Myers Squibb. M.K. Krzyzanowska: Advisory/Consultancy, Research grant/Funding (self): Eisai; Advisory/Consultancy: Bayer; Research grant/Funding (self): Exelixis; Research grant/Funding (self): Ipsen. T. Binder, R. Xie: Full/Part-time employment: Eisai Inc. C. Dutcus: Leadership role, Research grant/Funding (self), Full/Part-time employment: Eisai Inc. M.H. Taylor: Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy: Array BioPharma; Advisory/Consultancy: Loxo; Advisory/Consultancy: Bayer; Advisory/Consultancy: ArQule; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy: Novartis; Advisory/Consultancy: Sanofi/Genzyme. All other authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session